Ligand id: 6789

Name: etanercept

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: etanercept

Compound class Antibody
Approved drug? Yes (FDA (1998), EMA (2009))
International Nonproprietary Names
INN number INN
7783 etanercept
Enbrel® | Rhu Tnfr:Fc | TNFR-Fc | TNR 001
Database Links
Specialist databases
IMGT/mAb-DB 216
Other databases
CAS Registry No. 185243-69-0
ChEMBL Ligand CHEMBL1201572
DrugBank Ligand DB00005
GtoPdb PubChem SID 178103395
PubChem SID 135343504
Search PubMed clinical trials etanercept
Search PubMed titles etanercept
Search PubMed titles/abstracts etanercept
Wikipedia Etanercept
Etanercept is a TNFα inhibitor. It is a dimeric recombinant protein fusing the TNF receptor 2 (TNFRSF1B) to the Fc region of the human IgG1 antibody. Etanercept is used as a disease-modifying anti-rheumatic drug (DMARD).

Etanercept-szzs (Erelzi®) is US FDA approved for all indications included in the reference product's label.
Brenzys® (SB4; Samsung Bioepis) is approved in Korea and Canada and SB4 as Benepali® is approved in the EU.
Pfizer's biosimilar Lifmior® was EMA approved in Feb 2017.
Coherus Biosciences' CHS-0214 is in Phase 3 clinical trial for plaque psoriasis- see NCT02134210.
ENIA11 (opinercept, TuNEX®; Mycenax Biotech) received approval in Taiwan in Jan 2018 (see Reuters news brief). ENIA11 was evaluated with or against methotrexate in trial NCT01709760.